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Abstract The Cancer Immunotherapy Immunoguiding
Program has conducted an IFN- ELISPOT proWciency
panel to examine the inXuence of serum supplementation of
test media on assay performance. Sixteen European labora-
tories analyzed the same PBMC samples using diVerent
locally established protocols. Participants generated two
simultaneous data sets—one using medium supplemented
with serum and one without serum. Performances of the
two test conditions were compared by quantifying: (1) the
number of viable cells, (2) background spot formation
induced in the medium only control and (3) the ability to
detect antigen-speciWc T cell responses. The study demon-
strated that the number of viable cells recovered and the
overall background spot production were not signiWcantly
diVerent between the two conditions. Furthermore, overall
laboratory performance was equivalent for the two test con-
ditions; 11 out of 16 laboratories reported equal or greater
detection rates using serum-free medium, while 5 laborato-
ries reported decreased detections rates under serum-free
conditions. These results show that good performance of
the IFN- ELISPOT assay can be achieved under serum-
free conditions. Optimization of the protocol for serum-free
conditions should result in excellent detection rates and
eliminate the requirement of serum batch and stability test-
ing, allowing further harmonization of the assay.
Keywords ELISPOT · Serum free · Harmonization · 
T cell enumeration · Multicenter study
Introduction
The sensitive and accurate detection of vaccine-speciWc
T cells is a fundamental requirement for use of T cell
monitoring assays to facilitate the development of immuno-
therapeutics within clinical trials [1–3]. The CIMT Immu-
noguiding Program (CIP) is one of a number of recent
international initiatives that is committed to quality assur-
ance and harmonization of the most commonly used tech-
niques for cellular immunomonitoring, such as staining
with HLA-peptide multimers, Xow cytometric determina-
tion of intracellular cytokines and the IFN- ELISPOT
assay [4–7]. Through a series of proWciency testing panels,
critical variables in assay protocols have been identiWed
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and corrected, resulting in assay harmonization [8–10].
In addition, the panels provide the opportunity of external
validation for the participating laboratories. Here we report
on the analysis of the inXuence of serum supplement to
ELISPOT test media across diVerent protocols.
Many laboratories use either human or fetal calf serum
in their ELISPOT test medium to maintain the viability and
function of T cells. However, serum batches are known to
have unique compositions and immunological properties.
They require pre-testing, using control samples from repre-
sentative donors with known reactivities to identify batches
with low background reactivity and optimal antigen-spe-
ciWc spot production [11]. As serum pools are per deWnition
limited in size, rounds of testing to identify optimal serum
batches will have to be repeated on a regular basis. The use
of pre-tested serum batches, therefore, is a restricting factor
in its own right. Results obtained in laboratories with diVer-
ent batches may limit comparability between institutions;
similarly, results may diVer even when generated within
one center after switching to a new serum batch. It is also
well described that serum composition can change over
time [12, 13], which suggests that serum properties also
change during long-term storage. Consequently, if it were
possible to undertake ELISPOT assays under serum free
conditions without loss of sensitivity, this is likely to
reduce the variability of the assay and improve consistency
over time and between laboratories.
As yet there has been no collaborative study to evaluate
the need for serum in the medium used for the ELISPOT
assay across a variety of diVerent protocols. CIP has, there-
fore, initiated a proWciency panel with the speciWc aim of
identifying the impact of serum supplemented medium ver-
sus serum-free medium on the number of viable cells, back-
ground spot production and test performance. Here, we
report that the use of media without serum does not aVect
the number of viable cells, background spot production, or
detection rates, even when diVerent ELISPOT protocols
were used. However, the omission of serum requires ELI-
SPOT protocol optimization for each speciWc serum-free
medium.
Materials and methods
Preparation of PBMC samples and peptides
Anonymized buVy coats, collected from HLA-A*0201 pos-
itive healthy donors during routine blood donation, were
obtained from the National Blood Service in accordance
with local regulatory requirements. Peripheral blood mono-
nuclear cells (PBMC) were prepared in the laboratories of
the Cancer Sciences Division, University of Southampton,
UK. PBMC were isolated using Ficoll Paque™ Plus,
density gradient separation (GE Healthcare Lifesciences,
Buckinghamshire, UK), washed twice in RPMI 1640,
supplemented with 1 mM sodium pyruvate, 1% penicillin–
streptomycin-L-glutamine (Invitrogen Ltd, Paisley, UK).
PBMC were counted and stored in 1 ml aliquots at
1–2 £ 107/vial depending on the total cell number, in 40%
RPMI, 50% human AB serum and 10% DMSO using a
Nalgene controlled rate freezing container overnight at
¡80°C before transfer to liquid nitrogen vapor phase for
storage until required. The human AB serum used in cryo-
preservation had been batch-tested for use with minimal
background in the ELISPOT.
Two synthetic peptides (Peptide Protein Research, Fare-
ham, UK) for HLA-A*0201-restricted viral epitopes were
used as model antigens (inXuenza matrix protein58–66, GIL-
GFVFTL, and human CMV pp65495–503, NLVPMVATV).
Screening was performed at two central laboratories
(Southampton, UK and Leiden, The Netherlands) using
IFN- ELISPOT to identify inXuenza- and CMV-positive
reactivities. Five diVerent donors were selected, including
donors with no, low, medium or high numbers of detectable
T cells (range 0–100/105 PBMC) speciWc for one or both
model antigens. A total of seven antigen-speciWc T cell
responses were identiWed by extensive pretesting.
Participants and panel design
The ELISPOT proWciency panel consisted of 18 partici-
pants from 7 European countries (Denmark, Germany,
Poland, Sweden, Switzerland, The Netherlands and the
UK).
Coded PBMC samples (2 vials from each of 5 donors,
D1–D5) and synthetic peptides (aliquots of 1 g/l to be
used at a Wnal dilution of 1 g/ml) were shipped on dry ice,
together with instructions for testing. Participating centers
were asked to test the PBMC using an IFN- ELISPOT
assay separately under two conditions: (1) using medium
containing 5–10% serum, and (2) using one of the three
commonly used serum-free lymphocyte media [(1) AIM-V
from Gibco/Invitrogen, (2) C.T.L serum-free test medium
from Cellular Technology Limited or (3) X-Vivo 15 from
BioWhittaker], and to incorporate the four minimum
requirements established in earlier panel phases [10]: (1)
not to use allogeneic APCs, (2) to add ¸4 £ 105 lympho-
cytes per well, (3) to introduce a resting (recovery) time of
2–24 h before adding cells to the ELISPOT plate, and (4) to
perform the tests with triplicate wells. Cells plus medium
alone were used as negative control. A template pipetting
scheme was provided for consistency. Otherwise, assays
were performed according to locally established operating
procedures and reagents. Cells were counted immediately
after thawing and again after resting. On completion of the
assays including plate reading and auditing, participantsCancer Immunol Immunother (2010) 59:619–627 621
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complete a raw data report form and a questionnaire to pro-
vide full details of the reagents and protocol used. The tests
were performed within 12 weeks of sample shipment. No
central plate analysis was performed.
Analysis of results
Of the 18 participating laboratories, one center was unable
to recover a suYcient number of cells to perform the analy-
sis, and another completed only half of the requested analy-
sis. Sixteen complete data sets were, therefore, collected.
All but one of the laboratories considered themselves to be
“experienced” or “professional” in the use of ELISPOT
assay.
Response deWnition: the detection of inXuenza- and/or
CMV-speciWc reactivities was based on acceptance crite-
ria that had been established on previous CIP ELISPOT
panels [10]. Where insuYcient cells were recovered to
perform the test in triplicate the results were eliminated
from further analysis. Wells containing cells plus medium
only and no peptide were used as control triplicates. Wells
containing cells, medium plus peptides were deWned as
“experimental” triplicates. An experimental triplicate was
considered to be positive relative to the medium control
triplicate following a two-sided Student’s t test for
unpaired samples, when (1) P < 0.05 and (2) the mean spot
number was greater than threefold the mean spot number
of the medium control triplicate. Antigen-speciWc spots
were determined by subtracting the mean spot number in
the medium control triplicate from the mean spot number
in the experimental triplicate. The statistical analyses for
comparing the number of viable cells, background spots
and detection rates in serum supplemented or serum-free
media were calculated using a two sided, Student’s t test
for unpaired samples (P < 0.05).
Results
The impact of serum on the number of viable cells
Viable cells were counted immediately after thawing and
again after the mandatory resting phase in the assay.
Twelve centers performed manual counting using a micro-
scope and trypan blue exclusion. Three centers used
Guava-readers and one used a CASY cell counter, while
also providing complementary data sets for manual count-
ing. The mean number of viable cells based on trypan blue
exclusion (for all 5 donors) immediately after thawing was
10.6 § 3.3 £ 106 per vial, with a minimum of 4.3 and a
maximum of 18.1 £ 106 cells being reported by the partici-
pants. After resting, the mean number of viable cells was
decreased compared to direct counting following thawing,
with an average cell loss of approximately 31–40%
(Table 1). However, there was no signiWcant diVerence
between the results obtained in the presence of serum
(mean 7.3 £ 106 cells) compared to resting in the absence
of serum (mean 6.4 £ 106 cells) (Table 1; Fig. 1a). We con-
cluded that the number of viable cells was not compro-
mised in serum-free medium.
With the exception of one laboratory (ID09), all PBMC
were thawed at room temperature or 37°C. We did not
observe any correlation between the numbers of viable
cells and the type of medium used for thawing, the count-
ing method, and the duration of the resting phase [8 centers
included a short resting phase in their protocol (2–6 h)
and 8 centers used an overnight resting (14–20 h)]. Three
laboratories (ID03, ID07 and ID08) reported the use of
serum in their thawing medium, and it cannot be excluded
that these conditions inXuenced the test results. However,
the participants were instructed to use the same medium
for the resting phase as they would be using in the ELI-
SPOT assay. For serum-free conditions, this meant that
cells were rested in the absence of serum for 2–21 h.
A detailed list of thawing conditions is available in
Supplementary Table 1A.
Table 1 Number of viable PBMC after thawing and resting
The mean number of viable cells reported from all Wve donors after
thawing, and again after resting in either serum-supplemented or se-
rum-free medium are shown from left to right for each participating
center. The eight laboratories that introduced resting times below or
equal to 6 h are indicated with asterisks
Mean number of viable cells (Mio.)
After 
thawing
After resting 
in serum
After resting 
w/o serum
ID01 10.4 7.2 7.2
ID02* 6.6 4.7 4.3
ID03 11.5 9.8 n.d.
ID04 11.3 8.5 9.1
ID05* 18.1 10.6 6.1
ID07* 12.2 8.4 n.d.
ID08 10.0 6.3 6.7
ID09 8.9 5.2 4.9
ID11* 12.8 10.9 8.0
ID13 14.9 5.9 6.3
ID15* 10.5 8.2 8.4
ID16* 10.9 7.4 6.2
ID19* 7.5 n.d. n.d.
ID21 7.4 6.9 6.8
ID23 12.4 5.9 5.1
ID24* 4.3 3.2 3.8
Mean 10.6 7.3 6.4622 Cancer Immunol Immunother (2010) 59:619–627
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Background spot production under serum-supplemented 
and serum-free conditions
We then compared the induction of non-speciWc background
spots under serum and serum-free conditions. For this, back-
ground spot frequency was calculated for each center for
each of the Wve donors (D1–D5) under both conditions. As
background spot production in the wells containing cells
plus medium only was similar in quantity and distribution
among the group of 16 laboratories for all 5 donors (not
shown), the average values for all 5 donors, with serum and
without serum, were then compared directly (Fig. 1b). The
mean background spot values with and without serum were
not signiWcantly diVerent (4.9 and 4.7 per 100,000 PBMC,
respectively), suggesting that the presence of serum in the
medium does not aVect background spot production. The
median background spot production, which is less aVected
by the three outliers with high background was 1.1 (serum)
and 1.8 (serum-free) spots per 100,000. The background
values observed for the majority of laboratories was below
two spots per 100,000 PBMC.
Detection rates in serum-supplemented and serum-free 
conditions
We asked all participating centers to test inXuenza- and
CMV-reactivities of the Wve donor PBMC samples (seven
donor–antigen combinations) by performing the IFN-
ELISPOT assay using medium containing 5–10% serum
and using serum-free medium. Three of the 16 laboratories
routinely used serum-free medium in their protocol,
with the remaining 13 laboratories preferring the use of
pre-selected serum. Although the majority of participants
(12/13) used human AB serum, seven diVerent brands and
three non-commercially produced sera were reported,
whereas three laboratories did not specify the source of
their serum (Supplementary Table 1B). This emphasizes
the potential diYculties of standardizing this reagent.
The detection of inXuenza- and/or CMV-speciWc reactiv-
ities was subject to the strict acceptance criteria that we had
previously deWned ([10]; “Materials and methods”). Labo-
ratory performance was expressed as the detection rate, cal-
culated as the percentage of all potential responses that
were detected (Fig. 1c). In the whole group of centers,
detection rates were not signiWcantly diVerent for serum
and serum-free conditions (P =0 . 3 3 ,  S t u d e n t ’ s  t test).
Under test conditions with serum, 63.7% of all responses
were detected for the whole group, with seven laboratories
reporting >85% detection rates. Under serum-free condi-
tions, 52.9% of the responses were detected for the whole
group, and 4 laboratories reported >85% detection rates.
Comparison of the performance of individual laboratories
revealed that nine centers reported approximately equal
detection rates (<15% diVerence) under both conditions,
two centers generated better results and Wve centers
encountered decreased detection rates using serum-free
medium (>15% diVerence; Supplementary Table 2A).
Importantly, the majority (13/16) of laboratories had
optimized their protocols for use with serum and not for
serum-free conditions. These laboratories combined serum
with one of the following media: RPMI (6£), IMDM (4£),
X-Vivo 15 (2£) and Iscove (1£). The three laboratories
that normally used serum-free protocols added serum to
X-Vivo 15 (2£) or RPMI (1£). The analysis of these small
data sets did not reveal diVerences in the detection of posi-
tive responses in relation to the type of medium used.
Fig. 1 Overall results from sixteen IFN-ELISPOT protocols using
serum-supplemented and serum-free media. a Recovery of viable
PBMC using trypan blue and a manual haemocytometer, following
resting for 2–20 h. b Background spot production (spots per 100,000
PBMC) in the cells plus medium only control. c Detection rates, shown
as % of responses detected among the seven possible donor–antigen
combinations. The mean values for all samples (D1–D5) and all labs
(n = 16) were used to plot minimum and maximum value, the range
(error bars), inter-quartile range (boxes), median (horizontal line) and
mean (black triangle) for the whole group under serum supplemented
or serum-free conditions
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We then assessed whether the ability to detect antigen-
speciWc T cells correlated with the level of background
IFN- production (number of spots in the medium only
control). As shown in Fig. 2, the antigen-speciWc detection
rates increased as background spot production decreased,
with similar coeYcients of correlation of ¡0.66 for serum-
supplemented and ¡0.72 for serum-free conditions (Fig. 2).
The correlation was independent of whether the medium
contained serum, indicating that serum is not the major
factor contributing to the background spot frequency.
Qualitative and quantitative comparisons between 
laboratories
Comparisons of individual performances in detecting anti-
gen-speciWc T cells were made to examine inter-laboratory
variability, and to identify any protocol commonalities that
might impact on the performance. For this, results from the
assays performed under the preferred condition were used,
i.e., serum-supplemented medium and serum-free medium
for 13 and 3 labs (ID01, 04 and 16), respectively (Supple-
mentary Table 1A).
From the group of 16 participating centers, six individ-
ual laboratories were identiWed as “high performers”, by
having successfully detected 6 or 7 positive T cell
responses (detection rate >85%) using their preferred proto-
cols (Table 2A). The spot frequencies reported demonstrate
that in spite of the concordance between these six laborato-
ries in detecting inXuenza- and CMV-speciWc reactivities,
there was less agreement in the quantiWcation of antigen-
speciWc T cells. Variation between the 6 “high performers”
ranged from 74–153 spots/100,000 PBMC for the highest
response D3/CMV (mean frequency 116/100,000 PBMC)
to 1–13 spots/100,000 for the lowest response D2/CMV
(mean frequency 5/100,000 PBMC).
We investigated the possibility that the diVerences in
spot frequencies reported by participants might be inXu-
enced by the total number of cells seeded per well. As the
number of antigen-speciWc spots and the number of cells
seeded per well do not necessarily show a linear correla-
tion, spot numbers reported by laboratories using diVerent
numbers of cells per well might not be directly comparable.
In the case of the six high performing labs, Wve labs seeded
400,000 cells per well and one lab (ID09) used 450,000
PBMC per well. The latter laboratory reported spot fre-
quencies which were above the mean for all six success-
fully detected donor–antigen combinations (Table 2),
suggesting that the total number of seeded PBMC may
inXuence the outcome. Based on this, we investigated the
role of cell number and test performance in the whole group
of 16 labs. A total number of 11 labs seeded 400,000
PBMC per well, 3 labs seeded 450,000 PBMC (ID08, ID
09 and ID21) and 2 labs seeded 500,000 PBMC (ID05 and
ID13). However, no statistical diVerence for (1) the number
of background spots, (2) the number of antigen-speciWc
spots or (3) the detection rate for any of the three subgroups
was observed (not shown). The chance to detect a response
correlated with the estimated frequency of antigen-speciWc
cells within the sample (Table 2c), conWrming our previous
Wndings [10]. A summary of all results reported by the 16
participating centers for both conditions (serum vs. serum-
free) is provided in supplementary Tables 2A and B.
Finally, comparison of individual protocol variables
between the high performing laboratories did not identify
any commonalities (Table 3); the protocols of these six lab-
oratories were varied, with diVerent thawing conditions,
counting methods and resting periods. There were also
diVerences in the test medium, serum sources, type of ELI-
SPOT plates, antibody combinations and ELISPOT reader
used. This demonstrates that ELISPOT assays can be suc-
cessfully performed under completely diVerent, but for
each laboratory optimized, conditions.
Discussion
We have used a multicenter approach to study the impact of
serum use in a broad variety of ELISPOT protocols by
comparing the performance of 16 diVerent laboratories.
Numbers of viable cells after thawing and resting were
similar for both conditions (Fig. 1a), demonstrating that
cell quality was not compromised in serum-free media.
Similarly, there was little diVerence between the levels of
Fig. 2 Inverse correlation between background and detection rates.
Mean detection rates for each lab expressed, as the % positive respons-
es as deWned in “Materials and methods”, are plotted against the mean
cells plus medium only background (spots per 100,000 PBMC) using
serum supplemented (open triangles) and serum-free (Wlled circles)
media. Under both conditions, detection rate decreases as background
increases. Correlation co-eYcients: serum, ¡0.66; serum-free, ¡0.72
0
20
40
60
80
100
0.1 1 10 100
background spots per 100,000 PBMC 
%
 
r
e
s
p
o
n
s
e
s
 
d
e
t
e
c
t
e
d
serum no serum
trendline serum trendline no serum624 Cancer Immunol Immunother (2010) 59:619–627
123
background spot production under serum and serum-free
conditions (Fig. 1b), suggesting that serum is not a major
factor contributing to background spot detection. Overall
detection rates (expressed as the percentage of detected
among potentially detectable responses) did not diVer sig-
niWcantly between the two conditions (Fig. 1c). The fact
that four laboratories were able to detect >85% responses
without serum clearly illustrates that excellent results can
be obtained with serum-free protocols. However, Wve labo-
ratories (38%) found that the detection rates decreased
when they switched from using their serum-containing test
medium to a serum-free medium. It has to be emphasized
that 13/16 of the laboratories in this panel employ ELI-
SPOT protocols that had been optimized for the use of
serum supplemented medium. Based on these Wndings we
recommend the use of serum-free protocols to centers that
perform ELISPOT assays for monitoring immune
responses on a regular basis, as this should eliminate the
problems associated with batch-testing and serum stability, and
assist in the process of assay harmonization. Our observations
Table 2 Reported frequencies of antigen-speciWc T cells
Frequencies of antigen-speciWc spots were calculated after deducing the mean number of spots of the medium control triplicate (cells plus medium
only) from the mean number of spots of the experimental triplicate, and expressed as spots per 100,000 PBMC. Spot numbers per 100,000 PBMC
for the seven positive donor–antigen combinations are shown using favorite conditions for: (a) the six high performing laboratories (85.7–100%
detection rates), and (b) all other laboratories. Laboratories using serum-free protocols are underlined. Although performances were equivalent
qualitatively, the reported frequencies were not directly comparable across institutions
Median the median spot number per 100,000 PBMC, SD the standard deviation and CV the coeYcient of variation. Detection rates the detection
of responses for the whole group (n = 16), showing the median number of spots per 100,000 PBMC, the response classiWcation, deWned as “low”
(·6 antigen-speciWc spots per 100,000 PBMC), “moderate” (>6 and ·60 antigen-speciWc spots per 100,000 PBMC) or “high” (>60 antigen-
speciWc spots per 100,000 PBMC), the corresponding detection rates, empty boxes the results were not accepted as positive or the test was not done
a The use of CV as a quantitative measure of variation is of limited applicability for low responses
D1 (CMV) D2 (Flu) D2 (CMV) D3 (Flu) D3 (CMV) D4 (Flu) D5 (Flu)
(a) High performing labs
ID01 62 4 2 1 1 1 6 5 2 4
ID07 11 25 13 23 116 41
ID09 18 38 38 128 12 53
ID11 8 26 2 15 74 29
ID15 4 19 1 10 109 2 8
ID19 10 40 4 31 153 7 36
Median 9 25.5 3 22 116 6 32.5
S D 58 51 0 2 6 4 1 5
CV 51.97 29.51 110.82a 44.99 22.34 65.33a 48.49
(b) All other labs
ID02 41 12
ID03 4 9 76 2 4
ID04 8 51 2 16 17
ID05
ID08 115
ID13 6 12 8 64 2
ID16 38 34 184 48
ID21 7 14 11 55 3
ID23 66 63 9
ID24 10 89 16
Median 6.5 13 34 13.5 70 2 10.5
SD 2 18 45 12 46 8 17
CV 25.24 80.03 134.12a 68.29 53.25 122.67a 108.34
(c) Detection rates
Median (n = 16) 7 24 3 18 99 5 21
Response (class) Moderate Moderate Low Moderate High Low Moderate
Detection rate (%) 63 75 38 63 88 44 75Cancer Immunol Immunother (2010) 59:619–627 625
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are in line with those from a recent, single center study
[11], which concluded that removal of serum and addition
of low-dose IL-7 led to increased test performance when
applied to a speciWc ELISPOT protocol. During the review
process of our paper an additional inter-laboratory study
was published by Zhang et al. [14], where the use of eight
diVerent sera was compared to the use of the same serum-
free medium in a single optimized protocol. The results
showed that signal to noise ratio increased in the presence
of serum, and conWrmed that good performance can be
achieved using an optimized serum-free protocol. In con-
trast, our study of a variety of diVerent locally established
protocols clearly shows that removal of serum can increase
the performance in some laboratories, while decreasing per-
formance in others (i.e., increased background spot produc-
tion or lower numbers of antigen-speciWc spots), and that
ELISPOT assays can be successfully performed under
completely diVerent but for each laboratory optimized
conditions. We conclude that not all protocols support
high performance under serum-free conditions without
re-optimization.
The mean detection rate for the tests performed under
the routinely established protocol conditions was 65% rep-
resenting the detection of four (4.55) of the possible seven
responses. This relatively low detection rate is due to two
factors. In this panel phase, two of the seven responses that
could have been detected (the two donor–antigen combina-
tions D2/CMV and D4/Flu) were below or equal to six (on
average) antigen–speciWc spots/100,000 PBMC (Table 2).
In order to successfully detect these two very low responses
the background spot production should have been less or
equal to two spots which is below the mean background
spot production usually found in an average lab (CIP,
unpublished data). We, therefore, expected an “average”
lab to detect only Wve of the seven responses which would
have been a detection rate of 71.4%. The second reason for
the low overall detection rate was that very strict response
deWnition criteria were applied, which we had deWned in
previous rounds of inter-laboratory testing [10]. When we
applied the more commonly used response deWnition crite-
rion of twofold (instead of threefold) over background,
overall detection rate increased from 65 to 71.8% (for the
preferred condition of each lab) clearly showing that the
group of participants was experienced and representative of
an average laboratory.
The experience from the CIP ELISPOT proWciency
panel program and previous Wndings from Janetzki [8]
strongly suggested that background critically inXuences the
detection rate. The data from this panel conWrm that there
is a distinct relationship between the background spot
frequency and detection rates (Fig. 2) reinforcing the
importance of optimizing assay protocols to generate low
backgrounds.
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Six of the 16 participating laboratories were able to
detect 86–100% of the positive responses (6/7 or 7/7) using
their favoured conditions and were identiWed as “high
performers” (Table 2). Although the performances of
these laboratories were qualitatively equivalent, the anti-
gen-speciWc T cell frequencies were highly variable, ranging
between 1 and 13 spots/100,000 PBMC for the lowest
response (D2/CMV) and 74–153 spots/100,000 PBMC for
the highest response (D3/CMV). However, these six high
performing laboratories reported results with less variation
than the remaining ten laboratories (Table 2). High inter-
center variability has been observed previously in proW-
ciency panels organized by us and others [8, 10], especially
with low and moderate frequencies T cells, and it is clear
that quantitative comparison of results reported across insti-
tutions still remains a major problem in the Weld. Results
from the current panel continue to illustrate the diYculty in
decreasing inter-center variability in the ELISPOT assay,
even among experienced laboratories. To address this issue,
broadly available standard samples are urgently needed and
may even require the use of the same protocols [14]. This,
together with the implementation of external quality testing
projects and the generation of a commonly accepted frame-
work to report data from immunomonitoring assays [15], is
a major international challenge for achieving comparability
of data across institutions.
Comparison of the protocols used by high performing
laboratories revealed that these were diVerent from one
another (Table 3); there was no indication that any one fac-
tor in the protocol had critically inXuenced performance
with respect to the detection rate of T cell reactivities. On
the other hand, laboratories that used protocols that had
many commonalities could have diVerent detection rates.
Similar observations have been made previously by us and
others [8, 10] and suggest that high performance depends
on many factors, including the protocol components used
by each diVerent laboratory [14] as well as yet unidentiWed
parameters. For example, the laboratory environment in
which assays are performed may play an important role.
Immunological knowledge, experience, training, high
levels of quality control and assay validation [16–18] are
likely to be the key components of good assay perfor-
mances. CIP will now begin to systematically investigate
the inXuence of lab environment, quality assurance and test
validation on assay performance.
The current CIP panel was designed to compare the
eVects of serum supplementation or depletion on diVerent
locally established IFN ELISPOT protocols, and did not
include a systematic comparison of commercially available
media for lymphocyte culture and testing. A number of
laboratories of the CIP have actively participated in an
independent proWciency panel organized by the Cancer
Research Institute’s Cancer Vaccine Consortium (CRI-CVC),
which aimed at the comparison of 4 serum-free lymphocyte
media with the optimized laboratory medium supplemented
with serum [19]. Although the design of the CRI-CVC
panel diVered signiWcantly from that of the study reported
here, both programs reach similar results which supports
the overall conclusion on the use of serum-free test media
in ELISPOT assays. Recent literature suggests that the pro-
tocols and conditions (time lines, media, serum supplement,
etc.) used for preparing and freezing cellular material criti-
cally inXuence the cell quality and immunological function
[20–22]. These variables have not yet been systematically
investigated within a group applying a range of individual
protocols. CIP and CRI-CVC will, therefore, collabora-
tively organize a systematic analysis of these variables in a
representative testing group to generate a base for rational
development for highly sensitive ELISPOT assays with low
background spot induction.
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Collaborators of the ELISPOT proWciency panel of the CIP:
1. P. thor Straten, T. Kollgaard, Department of Haematol-
ogy, University Hospital, Centre for Cancer Immune
Therapy, Herlev, Denmark.
2. E. Kämpgen, M. Schmitt-Haendle, Department of
Dermatology, Dermatology Clinic Erlangen, Germany.
3. A. Mackensen, Department of Haematology, University
Clinic, Erlangen, Germany.
4. H. Veelken, M. Navarrete, A.-K. Kaskel, Medizinische
University Clinic, Freiburg, Germany.
5. D. Riemann, Institute of Medical Immunology, Martin
Luther University, Halle, Germany.
6. K. Giannopoulos, Clinical Immunology, Medical
University of Lublin, Poland.
7. E. Schultz, Department of Dermatology, University
Hospital, Marburg, Germany.
8. H. Pohla, Laboratory of Tumour Immunology,
Ludwig-Maximilians-University, Munich, Germany.
9. S. Walter, R. Mendrzyk, Immatics Biotechnologies,
Tübingen, Germany.
10. M. Schmitt, A. Schmitt, M. Götz, Department of
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11. M. Beyer, M. Fassnacht, S. Sbiera, Department of
Medicine I, University Hospital, Würzburg, Germany.
12. S. Paulie, A. Mesenholl, I. Areström, Mabtech,
Stockholm, Sweden.
13. R. Maier, Kantonal Hospital, St. Gallen, Switzerland.
14. C. Gouttefangeas, Department of Immunology,
University Tuebingen, Germany.
15. S. H. van der Burg, M.J.P. Welters, Department of
Immunohematology and Blood Transfusion and
Department of Clinical Oncology, Leiden University
Medical Center, Leiden, The Netherlands.
16. C. Ottensmeier, A. Mander, L. Low, Cancer Sciences
Division, University Hospitals, Southampton, UK.
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